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Abstract 
Intercellular communication sets the pace for transformed cells to survive and to thrive. 
Extracellular Vesicles (EVs), such as exosomes, microvesicles and large oncosomes, are 
involved in this process shuttling reciprocal signals and other molecules between transformed 
and stromal cells including fibroblasts, endothelial and immune cells. As a result, these cells 
are adapted or recruited to a constantly evolving cancer microenvironment. Moreover, EVs 
take part in the response to anticancer therapeutics not least by promoting drug resistance 
throughout the targeted tumor. Finally, circulating EVs can also transport important 
molecules to remote destinations in order to prime metastatic niches in an otherwise healthy 
tissue. Although the understanding of EV biology remains a major challenge in the field, 
their characteristics create new opportunities for advances in cancer diagnostics and 
therapeutics. 
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EVs at the interface of stromal communication 
Instigated by malignant cells the surrounding stroma undergoes a shake-up in its 
organization that supports cancerous growth. Crucial parts of this self-organization process 
include induction of metabolic changes, modifications of cell identities, initiation of neo-
vascularization and reprogramming of inert immune cells. In order to achieve these defining 
properties of the tumor microenvironment, cancer and non-cancer cells continuously 
exchange information brought together through cell-cell traversing gap junctions, tunneling 
nanotubes, and the secretion of effector molecules. One way to guarantee coordinated release 
of multiple “game” changing molecules relies on their packaging into membrane enclosed 
vesicles widely known as extracellular vesicles (EVs). “EVs” is a general term coined to 
denominate vesicle carriers that in fact hugely differ in their subcellular origin (Figure 1). 
They contain cargo such as lipids, proteins, various RNAs and DNA fragments and metabolic 
products. EVs may shuttle these molecules between neighbouring cells or via systemic 
transport to distant anatomic sites where they may induce signaling pathways or directly alter 
the phenotype of specified recipient cells.  
One kind of EVs finds its origin in secretory multi-vesicular bodies  that fuse with the 
plasma membrane releasing intraluminal vesicles, thereafter called exosomes (50-150nm in 
diameter). Another kind of EVs derive from vesicle budding at the plasma membrane. These 
are commonly called microvesicles (MVs) and are more heterogeneous in size (>100nm-1μm 
in diameter). Finally, large oncosomes (LOs, >1μm) have been described that differ in their 
buoyant density from the aforementioned vesicle types, are produced by plasma membrane 
blebbing (reviewed in 1, 18). All of those nanovesicles can be found in and isolated from 
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conditioned tissue culture medium of cancer and stromal cells but also from diverse body 
fluids such as cerebrospinal liquid, breast milk, urine or blood plasma. 
Due to their cargo specificity and their easy sourcing circulating EVs are being 
evaluated for the early diagnosis of various cancers. Indeed, EV cargo such as survivin may 
serve as marker for the early diagnosis of prostate cancer37, caveolin-1 for melanoma37, 
Glypican-1 for early pancreatic cancers50, and various miRNA profiles in colorectal cancer57 
and lung cancer12. 
EVs have recently also been implicated as direct mediators of the response of solid 
tumors to cytotoxic chemotherapy, and as putative ‘real-time’ biomarkers to assess individual 
drug responses. The evidence demonstrating modulation of drug sensitivity has centered on 
the EV-mediated transfer of proteins, mRNAs and miRNAs with the capacity to influence 
key anti-apoptotic or proliferative pathways between tumor cells or from the endothelium to 
tumor cells (see below).  
Navigating across these different aspects, this review will focus on the latest 
functional insights that EVs bear in intercellular communication during cancer progression.  
 
Modulation of EV composition 
Both exogenous as well as endogenous factors can modulate type, content and the 
number of released EVs. As discussed in more detail further below, hypoxia appears to be a 
strong driving force in the enhancement of EV shedding, resulting in pro-angiogenic effects. 
Furthermore, intra-tumoral hypoxic conditions augment MV release leading to increased 
risks of metastasis and mortality in patients with advanced breast cancer80. PH changes in the 
tumor microenvironment can also contribute to changes of the lipid composition of EVs62. In 
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addition, the cellular stress regulated protein TSAP6 that is under the control of the p53 
tumor suppressor was shown to enhance exosome production with possible effects on 
adjacent cells and the immune system82. Although our understanding of changes observed in 
EV composition under different physiological conditions is still minimal, they nevertheless 
may pave the way to novel, exciting avenues in diagnosis and treatment of cancers.  
In breast cancer for instance, the overexpression of oncogenes such as ERBB2/HER2 
in the mammary luminal epithelial cell line (HB4a) can shift the bias of EV content towards a 
malignant phenotype, as defined by the detection of oncodriver signaling components, 
including HER2, cell adhesion and cytoskeleton-remodeling components and sphingosine-1-
phosphate5. Similarly, oncogenic Ras-transformed NIH3T3 cells showed an increase of over 
34 proteins in EVs, including milk fat globule EGF factor 8 (lactadherin), collagen alpha-1 
(VI), 14-3-3 isoforms, guanine nucleotide-binding proteins (G proteins), the eukaryotic 
translation initiation factors elF-3 gamma and elF-5A accumulated (>2-fold)34. Mutated 
KRAS in colon cancer cells has also been reported to effect EV cargo composition towards 
tumor promoting factors including mutated KRAS itself as well as EGFR, SRC family 
kinases, and integrins, when compared to its isogenically matched wild-type KRAS cells17. 
Importantly, mutant cell-line-derived EVs positively enhanced cell growth of wild type 
cells17. Another oncogene, the melanoma cells secreted Wnt5A was also reported to induce 
the release of EVs20. Finally, tumorigenic viruses such as EBV can manipulate the secretion 
of EV bound cellular components, namely integrins, actin, IFN, and NFκB that subsequently 
activate cellular signaling in the surrounding stroma49.  
Although we now have evidence that oncogenes can directly modify cargo load, the 
knowledge of its consequences is still stuck in its infancy.  
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EVs reprogram cancer cell metabolism 
The development of cancers as a multi-stage process is often ignored in in vitro 
studies. As a result, we obtain a picture of cancer signaling and oncodriver activity that is 
blind to the spatiotemporal context of our observations, leaving us with the egg-chicken 
problem. EV composition presumably reflects the cellular physiology of their parent cells and 
can transport ‘seeding’ information to recipient cells. This implies that EVs carry the capacity 
to reprogram the cellular metabolism and re-wire cellular interactions (Figure 2). Therefore, 
EVs provide the rare opportunity to analyze the direct and causal effect that fractionated 
information has on oncogenic transformation.  
In this context, it is useful to understand that during the lifetime of a solid tumor its 
cells are subjected to enormous microenvironmental shifts, some of which are large enough 
to induce permanent transformations, may these be post-transcriptional and/or epigenetic or 
indeed metabolic, such as the Warburg effect. Additionally, during cancer development cell 
populations become increasingly heterogeneous. The extent to which an initial population is 
clonally diverse is still under debate; however, a hostile environment prompts malignant cells 
to adapt, primarily, by changes to their metabolic profiles, thus reprogramming the energetics 
of biosynthesis. For instance, the effect of hypoxia on HIF-1α, carbonic anhydrases (such as 
CAIX), the sodium/proton exchanger NHE1 and the glucose transporter Glut1 have been 
portrayed exquisitely in most solid tumors and paved the way for the discovery of metabolite 
import/export pumps demonstrating cancer cell plasticity by recycling their “waste material”.  
The best understood of such systems is provided by the proton-lactate symporters belonging 
to the family of monocarboxylate transporters (MCTs)27, 28 and their co-chaperone, the 
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glycoprotein CD14742. Under regimes of high glycolytic flux, lactic acid is initially exported 
in response to intracellular pH regulators. These alter cellular acid export providing the cell 
with an alkaline pH that in turn favors glycolysis and the import of glucose. However, the 
acidic burden resulting from glycolysis can eventually result in toxicity prompting the 
emergence of invasive cells81. Lactate can then be re-imported through the MCTs, a process 
known as lactate shuttling, and used as a source of energy in OXPHOS active cells via the 
lactate dehydrogenases (LDHA/LDHB) that convert lactate to pyruvate64. It is of great 
interest, therefore, that exosomes have been shown to contain high levels of Glut1, MCT4 
and CD147 as well as reduced phosphoglycerate kinase (PGK) levels68 because this finding 
appears consistent with the key elements characterizing the “reverse Warburg effect” shown 
to occur in stromal cells. In this scenario, metabolic EV content could ‘highjack’ the existing 
cellular program and re-wire it, presumably mimicking the cell of origin. The uptake and 
release of EVs is considered an energetically unfavorable event; cancer cells notoriously 
show reduced or lack of OXPHOS-derived ATP, elicit increased reliance on glycolysis, the 
pentose phosphate pathway and alternative energy sources such as lactate and acetate. 
However recent evidence has shown that EVs originating from prostate cancer cells can 
actually produce ATP from glycolysis and show reduced ATPase activity, when compared to 
EV populations released by normal prostate tissue (or prostasomes)68,  making their 
reception, rather than their release, the energetically favorable event. In many ways, EV 
formation by cancer cells appears more similar to an energetic investment made towards 
future re-homing by outsourcing their energy requirements. It would be of significant 
interest, and presumably possible, to re-engineer this machinery in the opposite direction and 
deliver tumor suppressor information from the microenvironment (such as fibroblasts, T-
lymphocytes or neutrophils) to the cancer cells. Instead, cancer associated fibroblasts (CAFs) 
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-derived EVs shuttle a range of metabolites to prostate and pancreatic cells, including lactate, 
glutamine, lipids, TCA cycle intermediates, resulting in reduced OXPHOS and increased 
reliance on glutamine and glycolysis84. This is at odds with the current understanding of 
metabolic reprogramming being an autonomous event occurring in cancer cells in response to 
nutrient deprivation. In this light, it appears that metabolic re-wiring is enhanced and could 
even be initiated by the tumor microenvironment, questioning much of the theoretical 
framework elaborated to explain malignant transformation and progression.  
KRAS activating mutations have been associated with oncodriver activity along the 
MAPK signaling pathway and have recently been shown to drive a glycolytic switch in 
NSCLC cells36. During PanIN de-differentiation KRAS mutations in acinar cells have been 
shown to drive PKD1-dependent mitochondrial ROS increases and that this event is the 
leading factor responsible for EGFR-mediated ADAM17 shedding43. Similarly, in KRAS 
mutant colorectal cancer, inhibition of the PI3K/mTOR pathway sensitizes cells to EGFR 
inhibitors8. Indeed, it has been reported that some EV populations form through DAG-
controlled fission and the secretion of which is dependent on the combined action of DGKα, 
which releases phosphatidic acid from diacylglycerol (DAG), and PKD1/248. Furthermore, 
pancreatic cancer patient-derived EVs contain oncogenic KRAS and subsequent analysis 
showed that the KRAS mutation status of EVs matched the primary tumor50. It is reasonable 
to hypothesize that EVs shuffle a diverse pool of signaling elements belonging to the KRAS 
pathway, as well as metabolites such as DAG, lactate and glutamine satisfying sufficient 
requirements to drive malignant transformation in healthy recipient cells. Proteomic profiling 
of EVs using stable isotope labeled amino acids in cell culture (SILAC) has further shown 
that exosomal cargo content is dependent on vesicle size52. LOs preferentially contain protein 
cargo targeted to mitochondrial metabolic processes including VDAC1/2, the solute carriers 
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SLC25A6 and SLC25A5 that are mitochondrial ADP/ATP translocators as well as the ATP 
synthase subunit ATP5B. Nano-sized EV cargo on the other hand contained higher amounts 
of proteins clustered towards glucose and glutamine metabolism and gluconeogenesis52. 
Because EV content seems size-dependent it is plausible that release and uptake of small EVs 
are coordinated separately from LOs. Cholesterol flux and functional lipid rafts affect the 
uptake of EVs in A375 melanoma cells63. We speculate that these and other mechanisms may 
in part help explain why certain cargo is tailored in an organotropic manner, thus favoring a 
tissue-specific metastatic phenotype. Metabolic reprogramming under stress appears to be 
one of the primary functions of EVs and HIF-1α has been detected in nasopharyngeal 
carcinoma exosomes where LMP1-induced transmission of transcriptionally active HIF-1α 
drives oncogenic processes2. 
Our current understanding of metabolic reprogramming events during cancer 
development is still widely elusive; in particular, the spatiotemporal order with which cells 
undergo metabolic reprogramming has not been fully evaluated. Further characterization of 
the feedback loops initiated by EVs on tumor cells and the stromal environment might 
provide critical missing pieces in this picture. 
 
Stromal effects of EVs 
EVs mediate fibroblasts and cancer cell changes 
Fibroblasts make up the bulk of stromal cells. Although hugely variable, even within 
the same kind of tumor, fibroblasts are in most cases the main contributor to the stroma. For 
instance, in invasive ductal carcinoma the average number of fibroblasts/myofibroblasts may 
reach up to 50-70% of the total stroma cell number. TGFβ, PDGF and FGF2 signaling-
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ligands in conjunction with other molecules including miRNAs can induce a cancer-activated 
or associated fibroblasts (CAFs)/myofibroblast phenotype characterized by increased 
proliferation rate, migratory properties and heightened deposition of ECM. CAFs originate 
from resident fibroblasts, through induction of epithelial-to-mesenchymal transition (EMT) 
or via recruited and reprogrammed mesenchymal stem cells (MSCs) and produce several 
growth factors such as HGF, VEGF and TGF35. Breast cancer cells (BCCs)-derived TGFβ-
EVs show the ability to differentiate adipose tissue-derived MSCs into α-smooth muscle actin 
positive CAFs utilizing the TGFβ/Smad pathway15. Furthermore, prostate cancer-derived 
EVs may induce CAFs from bone-marrow MSCs with pro-angiogenic and invasive 
functions16. This could be in part explained by the abundance of miR-1227 in LOs from the 
prostate cancer cell line RWPE-2 that enhances CAF migration properties55. EVs appear to 
induce CAFs, as recently substantiated by the findings that bladder cancer-derived EVs 
induce EMT in urothelial cells23. However, EVs from non-solid cancer chronic lymphocytic 
leukemia can also turn stromal endothelial cells and MSCs into CAFs60. On the other hand, 
stromal cells themselves are known to secrete EVs. In a human/mouse tissue culture system, 
Wnt11-EVs activated the Wnt-planar cell-polarity signaling pathway at the leading edge of 
BCCs eliciting cell migration. In that case, cancer cells and fibroblasts work together to 
assemble fibroblast EVs that are internalized by BCCs, loaded with Wnt11 protein and then 
re-released for paracrine signaling45.  
In a different context CAF EVs with increased levels of miRNA-21 profoundly 
impact ovarian cancer growth by suppressing apoptosis through binding to its novel target, 
APAF17. Finally, as discussed above CAF-derived EVs directly participate in metabolic 
reprogramming.  In aggregate, these few examples add to an increasing number of described 
EV functions in bidirectional cell interactions between fibroblasts and cancer cells. 
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EVs set the place and time for neo-angiogenesis 
Neo-angiogenesis allows tumors to get their own constant vascular supply of nutrients 
and oxygen, enabling them to grow above 2mm3 and become much more aggressive. One of 
the most recent advances in this field is the involvement of EVs in tumor-associated neo-
angiogenesis24, 61. Indeed, several groups reported the pro-angiogenic effect of tumor cell-
derived EVs on endothelial cells in different types of cancer such as glioblastoma71, 
leukaemia74, melanoma31 and ovarian cancer51. Since EVs can be taken up by endocytic-like 
processes, they may evade the ligand-receptor system on the cell surface influencing 
intracellular signaling and protein expression in endothelial cells25. As mentioned above, EVs 
can exert functions over short and long distances. In this way, pro-angiogenic EVs influence 
the neo-angiogenic program in the proximal tumor microenvironment but can also prime 
metastatic niches for angiogenetic events26, 31. 
 Pro-angiogenic factors such as VEGF, FGF, PDGF, interleukins, matrix 
metalloproteinase (MMPs), EGFR or signaling proteins including Rac1, Cdc42/Pak2 can be 
found among other proteins in tumor cells-derived EVs25, 41, 71, 78. The presence of these 
proteins in EVs brought novel aspects of tumor-associated neo-angiogenesis into the 
limelight. For instance, Al Nedawi et al. reported that upon uptake of tumor cell-derived EVs 
that contained oncogenic EGFR, endothelial cells establish a VEGF-dependent autocrine 
loop, a main mechanism in tumor neo-angiogenesis3. Such a process re-programs endothelial 
cells and consequently, strongly enhances neo-angiogenesis. More recently, Gopal et al 
showed that tumor cell-derived EVs are able to deliver signaling factors, such as Rac1 or 
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Pak2, or receptor proteins such as neuropilin 1, a co-receptor for VEGF, directly to 
endothelial cells promoting neo-angiogenesis25. In comparison to the classical 
“ligand/receptor” process, the authors called this phenomenon a “more direct avenue to 
induce angiogenesis” and suggest that it could be involved in metastatic spread25 (Figure 3). 
Some mRNAs and miRNAs found in EVs are thought to bespecifically involved in 
neo-angiogenesis78. For example in colorectal cancer, tumour-derived EVs can promote 
proliferation of endothelial cells and enhance their cell-cycle activities through M-phase 
related mRNAs, such as those coding for the centromere protein E (CENPE), PDZ binding 
kinase (PBK) or cyclin-dependent kinase 8 (CDK8)32. Additionally, the involvement of 
vesicular miRNAs in neo-angiogenesis has been studied such as miRNA-210 that exhibited 
strong pro-angiogenic activity22, 40, 83. Furthermore, miRNA-210 has been observed to 
suppress the expression of specific genes such as EFNA3 (coding for Ephrin-A3) in 
endothelial cells, resulting in enhanced neo-angiogenesis21, 39, 73. Colorectal carcinoma cells-
derived vesicular miRNA-9 shows pro-angiogenic effects through inhibiting the expression 
of suppressor of cytokine signaling 5 (SOCS 5), promoting the activation of the janus 
kinase/signal transducers and activators of transcription (JAK/STAT) signaling, a driver of 
endothelial cell migration85. Leukemia cells-derived exosomal miRNA-92a has also been 
shown to stimulate tumor associated neo-angiogenesis, through the inhibition of integrin α5 
expression77.  
Despite the direct pro-angiogenic effect of cancer cell-derived EVs on endothelial 
cells, such vesicles also promote neo-angiogenesis through indirect effects on other stromal 
resident cells. For example, leukemia-derived EVs can induce a CAF phenotype in stromal 
cells in the surrounding microenvironment, hence leading to increased expression of pro-
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angiogenic factors in such cells40, 60. Finally, EV-mediated crosstalk occurs also between 
endothelial cells themselves79.  
On the other hand EVs may act on tumor cells during neo-angiogenic processes since 
endothelial cells themselves have been shown to release EVs that can target tumor cells. 
Indeed, endothelial HUVEC cells were shown to secrete EVs containing miRNA such as 
miRNA-503 that were taken up by co-cultured tumor cells in vitro. MiRNA-503 was 
subsequently linked to response to neo-adjuvant chemotherapy in breast cancer9.  
  Several reports suggested that the increased number of tumor cells-derived EVs 
during neo-angiogenesis could be a reaction to a hypoxic condition, a key event in promoting 
neo-angiogenesis21, 62, 72. In addition, recent data showed that the composition of EVs may 
also depend on the hypoxic status of glioma cells41. In using glioma cell lines and patient-
derived cells EV signature composition was positively correlated to hypoxia.  This led to the 
observation that hypoxic tumor cell-derived EVs are more potent neo-angiogenesis inducers 
than EVs-derived from normoxic populations. Interestingly, hypoxic tumor cell-derived EVs 
execute this function by PI3K/Akt signaling modulation41. Furthermore, vesicular miRNA-
135b from hypoxic multiple myeloma cells can directly contribute to enhanced neo-
angiogenesis under chronic hypoxia through the inhibition of the factor inhibiting hypoxia-
inducible factor 1 (FIH-1) expression, promoting the activity of HIF-177. Other groups also 
reported on special selection processes for proteins and RNA content of tumor cell-derived 
EVs in response to hypoxia, providing them with specific pro-angiogenic functions38, 67, 69, 73. 
Finally, WNT5A signaling protein induces mechanisms that lead to the release of EVs from 
tumor cells containing pro-angiogenic factors such as VEGF20.  
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These data also suggest that different tumor types can release different EVs with 
variable outcome for neo-angiogenesis. For instance, tumor cells undergoing complete 
epithelial-mesenchymal transition (EMT) release EVs that are more effective at enhancing 
neo-angiogenesis than those undergoing intermediate EMT25. Similarly, for renal cancer, EVs 
with the most powerful pro-angiogenic activity were those derived from cancer stem cells 
(CSCs) and contained different angiogenic factors, compared to non-CSCs51.  
 
EVs tune the immune response. 
EVs, as mediators of intercellular communication, can modulate the activity and 
therefore the nature and vigor of diverse cellular immune response systems. Early data 
demonstrated the ability of Dendritic cell (DC)-derived EVs to stimulate an anti-tumor 
immune response as well as documented the presence of key MHC1 and MHCII proteins in 
EVs86.  More rigid functional evidence of intercellular shuttling of miRNAs with the ability 
to epigenetically effect target genes in a variety of DC cells was first obtained from EVs from 
different DC populations that showed varying miRNA signatures depending on their 
maturation state54; miRNA transfer has been demonstrated in both in vitro and in vivo settings 
and can effect a range of diverse processes. Transmission occurs sometimes in a 
unidirectional fashion for instance at the immune synapse from T-cell to antigen presenting 
cell, in an antigen driven fashion53. T-cell derived exosomes containing specific miRNA 
signatures have been recently shown to suppress T-H1 mediated immune responses in 
systemic diseases59.  There is now a growing body of evidence that suggests that cancer cells 
use EV transmitted nucleic acids and proteins as a way of enacting an immune escape.  
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Colorectal cancer cell-derived MV content such as TRAIL and FAS ligand has been 
demonstrated to induce T-cell death through the activation of the FAS-ligand32. This has also 
been demonstrated for other tumor types6.  In the context of hepatocellular carcinoma the 
release of heat-shock protein chaperones from EVs was shown to act as a decoy enabling a 
NK cell response to be directed away from tumor cells. In contrast, in resistant cell lines 
these HSP bearing EVs were upregulated46.  Circulating EVs in breast cancer similarly 
enable tumor growth by downregulating NK cell activity44. Tumor-derived EVs in 
nasopharyngeal cancer were found to induce T-reg activity and inhibit T cell proliferation in 
vitro. 
Whilst the above examples demonstrate that tumor-derived EVs can downregulate the 
immune response it appears that EVs from activated immune cells can also influence the 
tumor phenotype. For example, EVs from activated CD8+ T-cells can increase tumor 
immunogenicity by activating ERK and NFκB signaling through TNF-related signaling 
leading ultimately to the upregulation of MMP-9.  This chain of events increases the 
metastatic potential in melanoma and lung cancer11. In another chain of events pancreatic 
ductal adenocarcinomas cell-derived EVs can lead to pre-metastatic niche formation in 
sequential steps of induction of TGFβ signaling in Kupffer cells leading to extracellular 
matrix modification and subsequently an influx of bone marrow-derived macrophages to the 
liver, providing a favorable niche for liver metastasis19. 
 
EVs as ‘real-time’ biomarkers during cancer therapies 
Some of the most promising studies involving EV cargo modulation during drug 
treatment have been performed in glioblastoma multiforme (GBM). Levels of the DNA repair 
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enzymes APNG and MGMT are inversely correlated to response to the gold standard 
chemotherapeutic temozolomide30. EVs containing MGMT mRNA have been demonstrated 
to accurately reflect the levels of these enzymes in parental cells and in patients throughout 
treatment and therefore could serve as a potential ‘real-time’ biomarker of chemotherapy 
response during drug treatment70.  Similarly, circulating EVs containing the EGFRvIII splice 
variant that is thought to be predictive of response to EGFR inhibition were detectable in the 
serum of GBM patients but not in the 30 matched controls71.   
In the context of the neo-adjuvant treatment of breast carcinoma, elevated levels of 
the EV-bound MDR-glycoprotein BCRP were detected in non-responders compared to 
responders or treatment naïve patients14.  In addition, the receptor channel protein TRCP5, a 
known regulator of multidrug resistance glycoprotein-P, was required for EV formation in 
anthracycline resistant breast carcinoma cell lines.  Moreover, EVs containing TRCP5 protein 
from the same chemoresistant cells can enter chemosensitive cells and transmit resistance to 
cytotoxic chemotherapy. The same group also demonstrated elevated levels of TRCP5 
mRNA in circulating EVs from patients who did not respond to chemotherapy47.   
Horizontal transfer of nucleic acids has been postulated as one mechanism that can 
alter apoptotic and proliferative cell responses during cancer treatment.  Indeed, EVs from 
triple negative breast cancer cells in vitro can evoke proliferative and angiogenic properties in 
recipient cells that are similar to those seen in the parental cell line56.  A recent study 
elaborating on this work additionally demonstrated transfer of miRNAs including mir-100, 
miR-222, miR -17 and miR-30a through exosomes in breast cancer cell lines with the effect 
of modulating target genes which can be critical to drug response. For instance the transfer of 
miR-222 specifically caused PTEN mRNA downregulation in recipient cells.  The 
subsequent apoptotic response to doxorubicin was also reduced13. In addition to miRNAs, 
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proteins transported by EVs have also been shown to modify the apoptotic response. The key 
negative regulator of AKT/PI3 kinase signaling PTEN for instance has been identified as EV 
cargo eliciting active phosphatase function in the recipient cell65.  
Only a few studies have been published on the role of EVs in modulating a response 
to more specific targeted treatments.  One such study explored the role of EV transfer 
between cetuximab resistant and sensitive colorectal cancer cell lines in vitro. Although an 
effect on cell viability was observed, this effect turned out to be rather modest66. Recently, 
IncARSR (Inc RNA Activated in renal cell carcinoma (RCC) with Sunitinib Resistance) has 
been shown to promote sunitinib resistance via its EV bound transfer to sensitive RCC cells 
where it competitively binds miR-34/miR-449. Decreasing the levels of those miRNAs 
facilitates AXL and c-MET expression in RCC cells, rendering IncARSR as a hopeful 
predictor for sunitinib resistance. Although these few examples seem quite promising it 
remains widely unexplored and elusive whether EVs are indeed significant contributors to 
either intrinsic or acquired resistance to the plethora of FDA-approved small molecule 
inhibitors currently in clinical use.  
For anti-angiogenic therapies more data are available overall concluding on positive 
effects of EVs in modulating drug response.  Raimondo et al. analyzed the occurring changes 
in EV composition and evaluated their effects on drug treatment responses67. Interestingly, 
angiogenic factors present in EVs correlated with patients that were likely to benefit from a 
particular anti-angiogenic therapy. In addition, EV-dependent mechanisms could be 
implicated in the refractoriness of some tumor cells to current anti-angiogenic therapies, as 
observed for glioblastomas in response to bevacizumab. Finally, anti-angiogenic therapies 
could alter the pro-angiogenic properties of EVs, suggesting this as a new strategy to 
18 
 
decrease tumor-associated vasculature and tumor resistance29. Taken together the interference 
with EV communication could potentially have a strong anti-angiogenic effect3, 40. 
Studying EV-based therapies, some groups have explored the utilization of EVs as 
therapeutic delivery systems. Taking advantage of EVs in delivering specific RNAs designed 
to alter the phenotype of malignant cells could prove an attractive prospect.  Such a prospect 
was successfully executed by engineering let-7a miRNA containing EVs to modify EGFR 
expression in breast cancer cell lines leading to dramatic effects on tumor growth58.  
Similarly, delivery of extrinsically administered siRNA using exosomes in a murine setting 
has been demonstrated recently4 to be effective in knocking down a central nervous system 
specific protein. These promising sets of data suggest that this technology is now emerging 
allowing targeted use of extrinsically generated EVs in order to counteract tumors. 
 
Conclusion and outlook 
 Cumulatively, the studies briefly described make a resounding case for the 
involvement of EVs in all stages during cancer development. However, most of the 
aforementioned results are gathered from tissue culture experiments generating non 
physiological vesicle concentration levels. Therefore, it would be vital to substantiate these 
findings in more rigorous in vivo settings. These undertakings are currently hampered by 
considerable gaps in our knowledge of EV biogenesis and a lack of available in vivo tools75. 
It is interesting to note that, although EV formation occurs in all cells, most of our knowledge 
about their function stems from cells that have adapted to malignant transformation, while 
our knowledge about their roles in healthy tissue homeostasis lags behind. We have discussed 
the release and reception of cargo containing signaling molecules, as well as metabolic and 
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growth regulators, shuttled between tumor cells and their surrounding microenvironment. In 
this regard, it is the abundance or rather the delicate mixture of these molecules that charge 
EVs with cell transforming “superpowers”. Like Trojan horses they may cross the cell barrier 
and reprogram cellular functions in favor of the malignant cells. However, these properties 
also make them formidable candidates for cancer diagnostics as well as for novel therapeutic 
approaches. Firstly, their composition may hold important clues about the type and stage of 
various types of cancers and also reveal possible new targets.  Secondly, they could 
potentially be designed for the purpose of targeted intervention including the stimulation of 
local autoimmune responses or for the ‘trapping’ of disseminating cancer cells. Thirdly, 
during cancer treatment, EVs may switch their composition and may therefore exhibit traits 
for ‘real-time’ monitoring of therapeutic efficiency. However, while we make incremental 
progress in exploring all those possibilities many questions remain still unresolved. In 
particular those concerning their biogenesis, cargo selection and loading, as well as the 
mechanisms involved in their uptake, cargo liberation and incorporation into the context of 
the recipient cells.  The incentives to investigate the functional connotations of EVs promise 
to change our understanding of cancer biology and potentially of how to tackle this complex 
set of diseases. 
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Figure legends 
 Figure 1 EV biogenesis. EVs can form from the endomembrane system or through 
budding/blebbing from the plasma membrane. The best-described pathway for the production 
of exosomes starts at the plasma membrane through endocytosis at cholesterol enriched lipid 
raft domains. The subsequently generated early endosomes (EE) fuse in a number of fusion 
events and concomitantly mature to late endosomes (LE) that can then form intraluminal 
vesicles (ILVs) by invaginations and pinching of the limiting membrane. The product is 
referred to as a multi-vesicular body (MVB). MVBs are then either destined for the fusion 
with the lysosomal compartment leading to cargo degradation or are tagged for fusion with 
the plasma membrane thereby releasing ILVs, thereafter called exosomes. The orchestrated 
redistribution of membrane lipids, sphingosine metabolites10, 76 and/or the ESCRT 
machinery33 have been reported to have crucial functions in exosomes and MV biogenesis. 
Large Oncosomes derived by membrane blebbing can be artificially induced through knock-
down of the cytoskeletal protein DIAPH352. 
21 
 
Figure 2 Schematic representation of the flow of information regulated by EVs and LOs 
during metabolic reprogramming. EVs from glycolytic cancer cells can contain 
information that is fed to malignant or non-transformed cells (of cancer or stromal origin) and 
cause metabolic changes. For instance significant alterations can be induced in CAFs that in 
turn respond by the release of EVs containing sufficient material to sustain the cancer cell 
metabolism. This intercellular reprogramming evidences the dependency between the tumor 
and its adapted microenvironment whereby EVs can be seen as outsourced ‘investments’ 
undertaken to deliver metabolites and other material that promote tumor growth. 
Figure 3 EV-mediated transfer versus the secretion of soluble molecules bound for 
ligand/receptor interactions. Local diffusion of proteins such as cytokines, chemokines or 
growth factors (exemplified for tumor to endothelial cells delivery) allows the engagement 
with their respective receptors on proximal located cells. In contrast, tumor cell-derived EVs 
allow the transfer of diffusible factors but also that of receptors, intracellular signalling 
mediators and RNAs all protected from degrading enzymes in the microenvironment 
allowing systemic transport via bodily-fluids such as blood or the lymph for their 
distribution. Thus, EVs can transfer their content not only to neighbouring stromal cells but 
also to potentially remote locations of future metastatic sites. The delivery of EV cargo to 
target cells may circumvent the necessity of specific ligand/receptor interactions. 
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